Marty,
All good questions. I almost bought NEOT as soon as I saw it, but couldn't understand why the price was where it was -- and still is -- so I did some DD to see if they were considered an also-ran for some reason. Cerebrolysin is the only neurotrophin I found that is actually on the market. Why Ebewe doesn't crow more about having it in Phase III trials here, I don't know. I haven't been able to find anything about the trials, so comparing data with NEOT's can't be done. Maybe if I hunt in the FDA site. It works, but I don't know how well, or if there are side effects. Frustrating.
I believe GLFD and NEOT were doing preclinical research in this area at the same time, but Amgen has dragged its feet, and it seems that GLFD is now way behind. I couldn't say why Amgen has taken the slow path. Glad I didn't buy GLFD, either. If they didn't have so much cash, they'd be a lot cheaper, as they just aren't getting their technology developed fast enough to compete. Did you notice NeuroInvestor never replied to my spate of DD challenging his view that GLFD had such a great program?
Anyhow, at the moment, despite NEOT's promise, I'm in the wait 11 months and then buy it camp, myself. The current psychology towards small biotechs seems to be "let's see if they can market the stuff" unless the trial data are especially compelling. Look at Cor Therapeutics, for example, or Ligand or Isis. You can't fight the herd mindset and win. I keep an eye on it, though, and if something seems to change the Street's perception for the better, I'll be looking to get in. And if I can find a valid reason for NEOT's being ignored like this, I'll post it.
Cheers, Tuck |
